Status: Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) as measured by the change in 6-Minute Walk Distance.
Participants needed: 540
Trial details
Phase: Phase 3Age: 18-85Biological sex: AllType: InterventionalSponsor: Tenax Therapeutics, Inc.Updated: Mar 16, 2026Locations: 92
Eligibility criteria
Men or women, ≥18 to 85 years of age [+7]
A diagnosis of PH WHO Groups 1, 3, 4, or 5 [+7]